Literature DB >> 15195744

Registration of resected lung cancer in Niigata Prefecture.

Takehiro Watanabe1, Tatsuhiko Hirono, Teruaki Koike, Masanori Tsuchida, Kenichi Togashi, Kenji Nakayama, Masatomo Yazawa, Tsuyoshi Koyashiki, Hiroshi Kanazawa.   

Abstract

OBJECTIVES: Our registration of surgically treated lung cancer patients in Niigata Prefecture began in 2001. The purpose of this study was to identify the characteristics of patients and surgical treatment of lung cancer.
METHODS: All patients who underwent resection for lung cancer in Niigata Prefecture from January 2001 to December 2002 were eligible for registration. A total of 31 medical data for each patient were registered.
RESULTS: During the 2-year period, 1,211 patients were registered. A total of 605 cases (50%) were detected by mass screening, and 874 cases (72%) were diagnosed preoperatively. There were 718 (59%) c-stage IA cases and 317 (26%) c-stage IB cases. The most common operative procedure was lobectomy; 850 patients underwent single lobectomy. Limited resection was performed in 301 patients (25%), and video-assisted thoracoscopic surgery in 193 (16%). The most common histological type was adenocarcinoma in 860 cases (71%), followed by squamous cell carcinoma in 273 (23%). Pathologic staging yielded stage IA in 635 cases (52%) and stage IB in 262 (22%).
CONCLUSIONS: The results of our registration demonstrate a very high ratio of surgically treated stage IA cases in Niigata Prefecture and that limited resection was performed in many patients. Accumulation of these data will reveal the characteristics of lung cancer surgically treated in Niigata Prefecture and will provide a basis for determining the future course of surgical treatment for lung cancer. Registration is continuing, and it will provide new and useful information about lung cancer, eventually including 5-year survival data.

Entities:  

Mesh:

Year:  2004        PMID: 15195744     DOI: 10.1007/s11748-004-0115-y

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  8 in total

Review 1.  [Lung cancer].

Authors:  N Hara; Y Nakanishi
Journal:  Nihon Rinsho       Date:  2001-11

2.  Thoracic and cardiovascular surgery in Japan during 2000. Annual report by the Japanese Association for Thoracic Surgery.

Authors: 
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-09

3.  Prospective study of thoracoscopic limited resection for ground-glass opacity selected by computed tomography.

Authors:  Masao Nakata; Shigeki Sawada; Hideyuki Saeki; Shigemitsu Takashima; Hiroshi Mogami; Norihiro Teramoto; Kenji Eguchi
Journal:  Ann Thorac Surg       Date:  2003-05       Impact factor: 4.330

4.  Revisions in the International System for Staging Lung Cancer.

Authors:  C F Mountain
Journal:  Chest       Date:  1997-06       Impact factor: 9.410

5.  The influence of lung cancer mass screening on surgical results.

Authors:  T Koike; M Terashima; T Takizawa; M Haga; Y Kurita; A Yokoyama; H Misawa
Journal:  Lung Cancer       Date:  1999-05       Impact factor: 5.705

6.  Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung.

Authors:  Y Yamato; M Tsuchida; T Watanabe; T Aoki; N Koizumi; H Umezu; J Hayashi
Journal:  Ann Thorac Surg       Date:  2001-03       Impact factor: 4.330

7.  Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer.

Authors:  Teruaki Koike; Yasushi Yamato; Katsuo Yoshiya; Takehiko Shimoyama; Ryuta Suzuki
Journal:  J Thorac Cardiovasc Surg       Date:  2003-04       Impact factor: 5.209

8.  An evaluation of screening for lung cancer in Niigata Prefecture, Japan: a population-based case-control study.

Authors:  H Tsukada; Y Kurita; A Yokoyama; S Wakai; T Nakayama; M Sagawa; H Misawa
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

  8 in total
  1 in total

1.  Epidermal growth factor receptor in pancreatic cancer.

Authors:  Melissa Oliveira-Cunha; William G Newman; Ajith K Siriwardena
Journal:  Cancers (Basel)       Date:  2011-03-24       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.